MDCX
Medicus Pharma Ltd. Common Stock
There isn't enough reported data to score MDCX yet.
MDCX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
MDCX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
MDCX PE Valuation
MDCX has no meaningful PE right now: it lost money over the past year.
MDCX Forward outlook
There aren't enough analyst estimates for MDCX to show an outlook.
MDCX Earnings Per Share
MDCX Quarterly Revenue
MDCX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.9M | -$9.2M |
| Q2 2026 | -$7M | -$1.5M |
| Q1 2026 | -$9M | -$5M |
MDCX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +18% | +203K shares |
| 1 year | +357% | +1M shares |
MDCX has 1M diluted shares, up 357% from a year ago.
MDCX Net Leverage
MDCX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MDCX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.2 | Oversold |
| Stochastic | 0.6 | Oversold |
MDCX's weekly RSI is 25 (oversold) and its Stochastic is 1 (oversold).
MDCX PE vs Healthcare Sector
MDCX has no meaningful PE right now: it lost money over the past year.
MDCX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.94 | 56% below |
| 20 week MA | $10.2 | 83% below |
| 50 week MA | $29.9 | 94% below |
| 100 week MA | $90.9 | 98% below |
MDCX is in a downtrend: it's below all four of its weekly moving averages, and 98% below its 100-week average.
MDCX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $112.0 | $130.0 | +16% |
| 2025 | $130.0 | $78.5 | -40% |
| 2026 YTD | $78.5 | $1.72 | -98% |
MDCX has finished lower in one of the last two years. It's down 98% so far in 2026.